Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06536101
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Melanoma Stage IVSolid Tumor
- Interventions
- Drug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 117
- Registration Number
- NCT06425926
- Locations
- 🇺🇸
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 111
- Registration Number
- NCT06028074
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
News
No news found